Twitter Beğeni Hilesi

⭐️Nice editorial on “Neoadjuvant Immunotherapy in Breast Cancer - from #ClinicalTrials to #Practice” Dr. E Mittendorf Sara Tolaney JAMA Oncology JAMA jamanetwork.com/journals/jamao…

I am deeply honored to have been selected by ESMO - Eur. Oncology for this opportunity Gustave Roussy. Thank you to my incredible mentors G Curigliano MD PhD and FabriceAndre for their guidance. Thank you to Barbara Pistilli , Fernanda Mosele and @CarmeCriscit for all the support. See you in Barcelona! 🇪🇸

In DB04/06, T-DXd showed similar activity for MBC across HER2 IHC groups Could a more sensitive assay better predict the activity of T-DXd? At #ESMO24 we will present the first data of T-DXd prediction with #HSHER2, which provides the quantitative amount of HER2 in attomols/mm2

Better methods to quantify HER2 are highly needed. Glad to see data presented soon! #ESMO2024 #bcsm

End of the gold run for Frontiers and MDPI. 1/2

🌞We had an amazing time at the BOC department picnic this past weekend @TrilliumBrewing Fenway🌞From giant Jenga and cornhole to face painting, balloon art and ice cream treats, there was fun for everyone. Special thanks to all who joined us for the fun day!

Hot off the press in Annals of Oncology: Is adjuvant ribociclib ready for prime time? Recommended read in preparation for the NATALEE 4y update at #ESMO24 annalsofoncology.org/article/S0923-…

Un Ministro della Repubblica deve riferire in Parlamento. Non usare il #TG1 per confessare i suoi rapporti personali con la #Boccia, chiedere scusa alla moglie e mostrare pubblicamente le ricevute #Sangiuliano

Two superstars (Dr Hope Rugo Dr Sara Tolaney talking about HR+, HER2- early breast cancer #bcsm

An excellent read. Looking forward to seeing the #ESMO24 data. Will be interesting to see what happens if there is an FDA approval for adjuvant ribociclib…and especially how we think about it in the node negative population.

Adj abemaciclib preferred for high-risk HR+ EBC due to longer follow-up, deeper benefits, & shorter ⏰ of Rx. For patients intolerant to abema, ribociclib could be an option, especially for those outside monarchE with high-risk features. #OncTwitter OncoAlert #bcsm Sara Tolaney

🔍 Top 10 Breast Cancer Abstracts at ESMO - Eur. Oncology 2024 📊 Paolo Tarantino highlights must-see abstracts, from phase 3 readouts to novel ADCs and targeted drugs Have a look at the top 10 picks: oncodaily.com/blog/136264 #Cancer #Health #Medicine #OncoDaily #Oncology

Why is #SGBCC2025 a must-attend for young doctors? Hear it directly from Harold Burstein, a member of our Scientific Committee 🌟 #YoungDoctors #MedicalEducation #BreastCancerCare #SGBCC2025 #NetworkingOpportunity #Win

👉 Already registered for the ESMO Congress 2024? Delegates can view and download the contents of the Virtual Congress Bag.🌐 Get your congress bag today! #ESMO24 🔗 ow.ly/akGU50TggFh

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC! - #NIAGARA - #KN522 - #NATALEE - #DB12 - #MARIPOSA2 - #KRYSTAL12 - #NICHE2 - #SAKK41 - #POD1UM - #KN811 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ESMO - Eur. Oncology OncoAlert

Thank you TIME for highlighting our work in Kidney Cancer at Dana-Farber and Dana-Farber Lank Center for Genitourinary Oncology time.com/7018184/kidney…

Interesting real world analysis of outcomes with chemotherapy in HR+/HER2- MBC. Most used first line chemo: capecitabine. rwPFS for 1L chemo ~7 months, progressively shorter for subsequent lines. Consistent with recent trials in this space. #bcsm esmoopen.com/article/S2059-…

Paolo Tarantino reviews key #ESMO24 abstracts, covering updates from phase 3 results to innovative ADCs and targeted therapies. Explore his the top 10 picks below👇 x.com/oncodaily/stat…

Proud of joining this terrific group of oncologists and friends to contribute as ESMO Ambassador for #ESMO24

🔥 Catch this must-see at #ESMO24! Dive into advanced HR-positive MBC treatments 💉 with Javier Cortes MD PhD, Aditya Bardia, MD, Paolo Tarantino. Boost your clinical expertise and learn the latest approaches. Get details here! 📲 ms.spr.ly/6010mGVBo